A bald groom was beaten by the family of the bride for wearing a wig. The conversation discusses the cultural stigma around baldness in India and the consequences of deception in arranged marriages.
A user on finasteride for 7+ months shared bloodwork results, questioning if high DHT levels and testosterone could affect cholesterol. Replies suggest consulting a doctor and question the high testosterone levels.
The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.
Kitchen_Plastic_2847 had been fighting hair loss since 2019-2020 and was initially successful in regrowing his hair with finasteride. However, after contracting Covid three times back to back at the start of 2021, he started to lose his hair again. He found a new dermatologist who prescribed him oral minoxidil along with finasteride, but eventually decided it wasn't worth spending all the money to try and save his hair.
A user with female pattern hair loss who tried minoxidil and various oils and supplements, but saw results only after taking iron tablets. The conversation also offered advice to get blood tests done to see if there are underlying issues causing the hair loss.
User Clay1211 shared 1-year progress using finasteride, minoxidil, and dermaroller for hair loss. Commenters expressed surprise and praised the impressive results.
Hair regrowth treatment involving 3aHSD enzyme shows 6% improvement in 18 weeks. Sulforaphane, L-Menthol, and Dexpanthenol are potential ingredients for new hair loss solution.
Hair loss treatments discussed include Propecia, Rogaine, Nizoral shampoo, and dermarolling. Users shared experiences and results, with some noticing improvements in hair growth and maintenance.
The conversation is about the potential release of GT20029 on the grey market and concerns about its safety and authenticity. One user advises waiting for the official release by Kintor.
The conversation discusses sourcing pure latanoprost from the gray market for research and making a homemade solution. Concerns about potential dangers and experiences with this method are raised.
The conversation is about which blood markers to test before starting a 5-AR inhibitor for hair loss. The user mentions already testing Total T, Free T, SHBG, Estradiol, Haematocrit, Red blood cell count, and White cell count, and asks if DHT or additional markers are needed.
Breezula, a hair loss treatment, is expected to cost around $100 a month and is anticipated to be released in 2026. The effectiveness of Breezula is debated, with some suggesting it loses effectiveness over time and others arguing it maintains hair compared to baseline.
The user experienced reduced hair loss using grey-market KX-826 alongside Minoxidil foam, achieving better results with Minoxidil liquid but restricted to foam due to an allergy. Initial side effects included shortness of breath, racing heart, and dizziness, which subsided after the first week.
The conversation is about which blood tests are essential to check before starting hair loss treatment with finasteride or dutasteride. The tests mentioned include DHT, PSA, Estrogen/Estradiol, Testosterone, FSH, and LH.
The conversation discusses the availability of GT20029, a new topical hair loss treatment with fewer side effects than Minoxidil or finasteride. Users suggest using finasteride to preserve hair until GT20029 becomes available.
The conversation is about the potential availability of GT20029 on the black market and whether users would try it. Participants advise waiting for phase 3 trial results to ensure safety and efficacy.
The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.
The user is considering adding an anti-androgen, RU58841, to their current hair loss treatment routine due to receding hair. They are also contemplating waiting for Breezula or Pyrilutamide to become more affordable.
The conversation discusses the potential availability of a new hair loss treatment, GT20029, on the grey market, with users suggesting it could be within a year but advising against using grey market products due to safety concerns and complexity of the drug.
A new company is introducing a topical treatment combining Minoxidil, Finasteride, and Bimatoprost for hair loss. Users are also inquiring about updates on a minoxidil-enhancing shampoo from Applied Biology.
The conversation is about the possibility of obtaining Pyrilutamide, a hair loss treatment, once it becomes available in China, despite it not being approved by the US FDA yet. The user wants to use Pyrilutamide along with other treatments.
The conversation is about someone switching from Minoxidil and Finasteride to Redensyl, Procapil, and Capixyl serums due to anxiety over potential side effects, and they are inquiring about others' regrowth experiences with these serums. Some doctors in India have prescribed these serums, and the person knows others who are satisfied with the results.
Skin, Hair, and Nails by Pharmekal was withdrawn from the market. Users discuss alternative supplements and treatments like Minoxidil, finasteride, and RU58841.
New hair loss treatment called scube3 discussed with mixed opinions. Concerns about pharmaceutical companies preferring repetitive treatments over cures due to profit.
The conversation is about the anticipated release timeline for a hair loss treatment called GT20029. It may be available on the gray market in 1-2 years and officially in 3-4 years after completing clinical trials.
The results of using Pyrilutamide, a hair loss treatment available on the gray market, and other treatments such as Minoxidil, Finasteride and RU58841.
Pirfenidone is suggested to treat fibrosis and baldness by blocking inflammation markers and reducing collagen. It is also available as a gel for scar removal.
The conversation discusses why there are no FDA-approved NSAAs like RU58841 on the market, despite their potential superiority to 5AR inhibitors like finasteride. It explores the effectiveness of treatments like Minoxidil, finasteride, and RU58841 for hair loss.
The conversation discusses the uncertainty of the legitimacy of minoxidil products in the EU market and mentions baricitinib as an approved, but expensive alternative. A method to test for real minoxidil involves mixing it with bleach to see if it turns orange or brown.